ing a diagnosis of or treatment for CHF. This has been termed preclinical systolic dysfunction and may be common. [3] [4] [5] However, the prevalence of diastolic dysfunction and its relation to systolic dysfunction and recognized CHF in the community is unclear.
The efficacy of therapy to abort or delay the progression of preclinical systolic dysfunction to CHF is recognized by CHF practice guidelines. 6 Studies indicate that even simple Doppler evidence of diastolic dysfunction is an independent risk factor for the future development of CHF and cardiac death. 7, 8 Thus, if common, early recognition and treatment of preclinical systolic and diastolic dysfunction represent a potentially powerful strategy to reduce the incidence of CHF.
Our objective was to establish the prevalence of preclinical systolic and diastolic dysfunction and the prevalence of CHF in randomly selected residents of Olmsted County, Minnesota, 3 aged 45 years or older. Furthermore, we sought to determine whether the presence of diastolic dysfunction is independently predictive of all-cause mortality.
METHODS
In 1990, 96% of the 106 470 residents of Olmsted County were white. Other characteristics of this population have been previously described. [9] [10] [11] The Mayo Foundation institutional review board approved this study.
Using the resources of the Rochester Epidemiology Project, 10 a random sample of residents who were at least 45 years old as of January 1, 1997, was identified. Participants were enrolled and studied during a 3-year period, ending September 30, 2000 . Of the 4203 eligible residents invited, 2042 (47%) participated. Analysis of the medical records of 500 randomly selected residents who did not participate revealed similar age and sex distribution to that observed in participants and a similar prevalence of hypertension, coronary artery disease, previous myocardial infarction, diabetes, previous cardiovascular hospitalization, and CHF.
Community medical records for each participant were reviewed by trained nurse abstractors using established criteria for hypertension 12 or myocardial infarction. 13 In addition, clinical diagnoses of coronary artery disease and diabetes mellitus were recorded. Each participant underwent a focused physical examination that included measurement of blood pressure, height, and weight. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Each participant's medical records were reviewed to determine if any diagnosis of CHF had been made. If so, each medical encounter was reviewed to determine whether the documented clinical information fulfilled Framingham criteria 9 (validated CHF; BOX). Participants with no CHF diagnosis but with either diastolic or systolic dysfunction at echocardiography were considered to have preclinical diastolic or systolic dysfunction. Such designation does not imply that the participant would definitely develop CHF or did not have symptoms, only that the participant had not sought evaluation or had not had an evaluation that resulted in a diagnosis of CHF.
Doppler Echocardiography
All echocardiograms were performed by 1 of 3 registered diagnostic cardiac sonographers who used the same echocardiographic instrument (HP-2500, Palo Alto, Calif) according to a standardized protocol and interpreted by a single echocardiologist (M.M.R.) who was masked to clinical data. Twodimensional (2-D) and color Doppler imaging were performed to screen for valvular disease.
In each participant, measurement of EF was performed by M-mode echocardiography using the modified Quinones formula, by the quantitative 2-D (biplane Simpson) method, and by the semiquantitative 2-D visual estimate method.
11, [14] [15] [16] [17] Each participant underwent pulsedwave Doppler examination of mitral inflow before and during Valsalva maneuver and of pulmonary venous inflow and Doppler tissue imaging of the mitral annulus. Diastolic function was categorized according to the progression of diastolic dysfunction: normal; mild, defined as impaired relaxation without evidence of increased filling pressures; moderate, defined as impaired 
Major Criteria
Paroxysmal nocturnal dyspnea Orthopnea Elevated jugular venous pressure Pulmonary rales Third heart sound Cardiomegaly on chest radiograph Pulmonary edema on chest radiograph
Minor Criteria
Peripheral edema Night cough Dyspnea on exertion Hepatomegaly Pleural effusion Heart rate Ͼ120/min Weight loss Ն4.5 kg in 5 days * *Weight loss Ն4.5 kg in 5 days is considered a major criterion if it occurred in response to therapy for congestive heart failure (CHF). A patient was considered to have validated CHF if 2 major criteria were present or 1 major and 2 minor criteria were present concurrently.
relaxation associated with moderate elevation of filling pressures or pseudonormal filling, and severe, defined as advanced reduction in compliance or reversible or fixed restrictive filling as previously described and validated (FIGURE 1) . 1 Participants with atrial fibrillation with DT Ͼ140 ms, other arrhythmia, fusion of E and A, or in whom diastolic parameters were not obtained, who had only 1 criterion suggesting moderate or severe diastolic dysfunction, or in whom diastolic parameters were borderline and suggestive of but not diagnostic of abnormality were classified as having indeterminate diastolic function. E, peak early filling velocity; A, velocity at atrial contraction; DT, deceleration time; Adur, A duration; ARdur, AR duration; S, systolic forward flow; D, diastolic forward flow; AR, pulmonary venous atrial reversal flow; e', velocity of mitral annulus early diastolic motion; a', velocity of mitral annulus motion with atrial systole; DT, mitral E velocity deceleration time.
*Corrected for E/A fusion. 40 As part of the Rochester Epidemiology Project infrastructure, mortality data on Olmsted County residents are routinely collected by reviewing community medical records, death certificates, and obituary notices. Participants were followed up until death or October 1, 2002, at which time they were censored. This provided 7000 person-years of follow-up, with a median (25th, 75th percentile) of 3.5 (2.9, 4.2) person-years of follow-up. Active surveillance of the first 41% (n=974) of the cohort recruited to participate in our study for a follow-up visit identified no additional deaths to those identified via the above mechanisms.
Statistical Methods
For each EF method, the corresponding distribution was summarized as the empirically estimated cumulative distribution function. The overall prevalence of systolic dysfunction was estimated for each method among participants from whom EF was obtained by that method with the corresponding 95% confidence interval (CI) based on the exact binomial distribution. Similar methods were used to estimate the overall prevalence of diastolic dysfunction. The association between the prevalence of systolic dysfunction with clinical variables was investigated using the 2 test for univariate associations and logistic regression when controlling for potential confounding variables. The Mantel-Haenszel 2 test of trend was used to investigate the association between the ordinal scale of diastolic dysfunction with dichotomous clinical variables and the Spearman correlation coefficient for continuous variables. Ordinal logistic regression was used to adjust the association of clinical variables with diastolic dysfunction for age and sex. The survival-free (of any cause) status was estimated using the Kaplan-Meier method and the association with diastolic dysfunction was assessed using the logrank test. The Cox proportional hazards regression model was used to adjust the association of diastolic dysfunction with all-cause mortality for age, sex, and EF. The proportional hazards assumption was evaluated and not rejected using methods developed by Grambsch and Therneau. 21 All analyses were done using SAS version 8 (SAS Institute, Cary, NC) except for the test of proportional hazards which was done using the survival analysis software in S-Plus Version 6.1.2 (Seattle, Wash).
RESULTS

Study Participants
The mean (SD) age of study participants was 62.8 (10.6) with 29.4% aged 45 through 54, 30.6% aged 55 through 64, 25.4% aged 65 through 74 years, and 14.6% aged 75 years or older. The mean (SD) BMI was 28.4 (5.41). Of the participants, 8.9% were current and 50.1% were former smokers, 4.5 had diabetes, 12.2% had a history of coronary artery disease, and 4.8 % had a previous myocardial infarction.
Congestive Heart Failure
The prevalence of any CHF diagnosis was 2.6% (95% CI, 1.9%-3.3%) with 21 participants (41%) having an EF higher than 50%. A validated diagnosis of CHF was present in 45 participants (2.2%; 95% CI, 1.6%-2.8%) with 20 (44%) of those having an EF higher than 50%. The mean (SD) time between CHF diagnosis and the echocardiogram was 4.9 (4.1) years (range, 0.1-16.2 years). The prevalence of validated CHF increased with age groups: 0.7% for those aged 45 through 54; 1.3% in those aged 55 through 64; 1.5% for those aged 65 through 74; and 8.4% for those aged 75 years or older. The P value with or without adjustment for sex was PϽ.001. The prevalence of validated CHF was 2.7% in men vs 1.7% in women (P=.11, without adjustment for age). When adjusted for age, CHF was slightly more common in men (P=.03).
Diastolic Dysfunction
Diastolic function was classified as normal or abnormal in 1779 participants (87.1%) and as indeterminate in 263 participants (12.9%). Among the 45 with 
Systolic Dysfunction
Any, ejection fraction Յ50% The cumulative distribution of EF within the population as assessed by the 3 techniques is displayed in FIGURE 2, which illustrates the prevalence of systolic dysfunction according to the EF level and method of measuring it.
In 1888 participants with a quantitative EF assessment, the prevalence was 6.5% (95% CI, 5.4%-7.6%) for those with an EF of 50% or less and was 1.8% (95% CI, 1.2%-2.4%) for those with an EF of 40% or less. Among 2036 participants whose EF was measured by the 2-D visual method, the prevalence was 6.0% (95% CI, 5.0%-7.1%) for those with an EF of 50% or less and was 2.0% (95% CI, 1.4%-2.5%) for those with an EF of 40% or less. The prevalence of systolic dysfunction was lower when restricting the population by using only 1 quantitative method (Figure 2) , was higher in men than women (TABLE 3) with and without controlling for age (PϽ.001 for all), and increased with age with and without adjustment for sex (PϽ.001 for all). Systolic dysfunction determined by the 2-D visual method was more common in participants with CD (Table 3 ). All associations were similar when only participants with quantitative EF assessment were examined.
Diastolic and Systolic Function Parameters
An EF of 50% or less was present in 1.4% of participants with normal, 10.5% with mild, 19.5% with moderate, 61.5% with severe, and 13.6% with indeterminate diastolic function. Overall, 100 participants (5.6%; 95% CI, 4.5%-6.7%) had moderate or severe diastolic dysfunction but had normal EF (isolated diastolic dysfunction).
Among subjects with normal EF and no CHF diagnosis, increasing severity of diastolic dysfunction was associated with a higher mean (SD) left ven- All-cause mortality (n = 48 deaths) was increased among those with diastolic dysfunction (FIGURE 4) . Multivariate analysis showed that diastolic dysfunction was predictive of allcause mortality even when controlling for age, sex, and EF (TABLE 5) .
COMMENT
This study provides the first estimates of the prevalence of diastolic dysfunction in the community as assessed by rigorous and hemodynamically validated Doppler criteria. Diastolic dysfunction was common and isolated diastolic dysfunction was as common as systolic dysfunction. The frequency of CHF increased dramatically with increasing severity of diastolic dysfunction. However, even severe diastolic dysfunction was often preclinical with no recognized CHF diagnosis. When controlling for age, sex, and EF both mild and moderate or severe diastolic dysfunction were predictive of all-cause mortality. Systolic dysfunction was also common. Although the frequency of CHF also increased with worsening systolic function, even among those with an EF of 40% or less, fewer than 50% of participants had a diagnosis of CHF. Simple clinical characteristics allow identification of individuals at highest risk for preclinical diastolic or systolic dysfunction.
A novel aspect of this study is our effort to describe the frequency of diastolic dysfunction and its association with systolic dysfunction and CHF in the population. These data are important because population-based studies 9, [22] [23] [24] have repeatedly demonstrated that 40% to 50% of individuals with CHF have normal EF, a finding we again confirm. Recent studies have documented that individuals with CHF and normal EF consistently demonstrate diastolic dysfunction when subjected to hemodynamic study and document that patients presenting with CHF and normal EF do not have transient systolic dysfunction. 2, 25 Furthermore, using more rudimentary indices to assess diastolic function, Aurigemma et al 7 documented that mitral inflow patterns suggesting mild or moderate or severe diastolic dysfunction were independently predictive of future development of CHF in free-living older volunteers. Bella et al 8 report that a mitral inflow pattern suggestive of diastolic dysfunction was associated with increased cardiac mortality, independent of pertinent covariates. In our study, we used more rigorous Doppler methods to characterize diastolic function, requiring that 2 indices proven as predictive of advanced diastolic dysfunction be present for assignment to the moderate or severe diastolic dysfunction category. We observed the previously described association between diastolic dysfunction and age. 26 These data are consistent with ageassociated increases in CVD and with studies suggesting that senescence itself may be associated with impairment in diastolic function. 27 The presence of diastolic dysfunction was closely associated with the presence of CVD, confirming the propensity of hypertension 28, 29 and coronary artery disease 28, 30 to produce diastolic dysfunction. Even confining the analysis to participants with normal EF and no CHF, worsening diastolic dysfunction was associated with increases in indexed left ventricular mass and left atrial volume. These structural findings support the Doppler evidence of diastolic dysfunction because the hypertrophied ventricle is more likely to display diastolic dysfunction and chronic increases in left atrial pressure associated with diastolic dysfunction would be expected to lead to atrial enlargement. Finally, we demonstrate that, as rigorously defined in our study, both mild and moderate or severe diastolic 31 Other populationbased studies have reported prevalence rates similar to ours when age, sex, and technique-specific rates were examined. 4, 32 Although the prevalence of systolic dysfunction increased with increasing severity of diastolic dysfunction, most participants with diastolic dysfunction had a normal EF. Indeed, moderate or severe isolated diastolic dysfunction was as common as systolic dysfunction.
The frequency of any and validated CHF diagnoses among patients with ventricular dysfunction increases with the severity of ventricular dysfunction, but even among those with advanced diastolic or systolic dysfunction, more than 50% have no CHF diagnosis or received no treatment. Although previous studies also suggest that up to 50% of patients with systolic dysfunction have preclinical systolic dysfunction, 3-5 the current data extend previous studies by examining both types of ventricular dysfunction known to be associated with the development of CHF, their relation to each other, and the frequency of CHF diagnosis. Easily identified high-risk groups have a higher prevalence of preclinical ventricular dysfunction.
The lifetime risk of developing CHF for those who have reached the age of 40 years is 20% for both men and women 33 and exceeds the lifetime risk of many conditions commonly screened for in the community. Prevention of CHF through the treatment of preclinical systolic dysfunction is recommended in CHF guidelines. 6 Although we acknowledge the lack of therapies proven to modify disease course in diastolic CHF, several clinical trials are underway. The current data are crucial if we are to be poised to extend the paradigm of prevention of CHF through treatment of preclinical systolic dysfunction to those with preclinical diastolic dysfunction. Screening strategies to detect preclinical ventricular dysfunction include Doppler echocardiography and potentially, measurement of plasma brain natriuretic peptide concentration (BNP). However, studies vary as to the sensitivity and specificity of BNP for the detection of systolic or diastolic dysfunction and more data are needed.
11, [34] [35] [36] [37] [38] [39] The Olmsted County population is primarily white and may not be representative of national demographics of diastolic and systolic dysfunction. Although comparison of the clinical characteristics of participants and nonparticipants did not reveal significant differences, preferential participation by subjects with or without disease cannot be excluded.
In the community, systolic dysfunction is frequently present in subjects without recognized CHF. Furthermore, diastolic dysfunction as rigorously defined by comprehensive Doppler techniques is common, often not accompanied by recognized CHF and associated with marked increases in allcause mortality. 
